FSC licenses children's allergy drug from Tris Pharma
Charlotte, N.C. —
FSC, based in Charlotte, said that it expects Karbinal ER will be available in U.S. pharmacies in time for the 2014 spring allergy season. The drug, an oral suspension, is approved for use in children as young as two years old. Tris received Food and Drug Administration approval on Karbinal ER in April.
Under the terms of the agreement, Tris will manufacture Karbinal ER using its proprietary technology. FSC will market the drug. FSC will pay Tris up to $20 million in milestones, dependent on sales of the drug. FSC will also pay Tris Pharma a double-digit royalty on net sales.
Please Log In to add a comment.
Best of TechWire Insider
- GoGown deal shows power, necessity of networking for startups
- New GSK oncology consortium targets combination therapies
- Fighting hospital infections: A Durham nurse's dream produces the GoGown
- From photos to out-of-this-world art: Raleigh firm's software transforms images
- LabCorp expands gene tests for cancer - but don't confuse these with 23andMe
- ChannelAdvisor: Mobile cuts deeply into PC share of online shopping
- Inside Appia's latest funding deal: Debt beats dilution
- Can Barley's bark win Super Bowl gold for Durham startup?
- Tech guru Mossberg changes gears, praises Republic Wireless
- Survey explodes myth of the poor VC-backed entrepreneur